• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Feb. 2, 2015

View Archived Issues

Obesity market gets more players; improving, but challenges remain

The approval of Takeda Pharmaceuticals U.S.A.'s and Orexigen Therapeutics Inc.'s Contrave (naltrexone and bupropion) in September and Saxenda (liraglutide) from Novo Nordisk A/S last month doubled the number of obesity drugs approved by the FDA in the last two and a half years. Read More

Biotech sector sets the pace despite turbulent capital markets

It was a volatile month for the capital markets at just one trading day left before the curtain closed on the first month of the year. The markets experienced wild swings throughout January. Despite the uncertainties, the industry has got off to a red hot start to the year with the BioWorld Biotech Blue Chip index, a price-weighted index that includes 20 of the top biotech companies by market cap, recording a strong 6.5 percent jump in value compared to the lackluster 1.1 percent drop in the Nasdaq composite Index and a 2.3 percent slide in the Dow Jones Industrial average over the same period. Read More

Week in review

Read More

Biotech money raised by month in 2014

Read More

Money raised by biotech Jan. 1 - Jan. 29, 2015

Read More

Word on the street

Read More

Week in Washington

Read More

U.S. public offering performance by underwriter, ranked by gross proceeds: January - December 2014

Read More

U.S. public offering performance by underwriter, ranked by after-market performance: January - December 2014

Read More

Lead underwriter performance on all U.S. offerings, ranked by gross proceeds: January - December 2014

Read More

Lead underwriter performance on all U.S. offerings, ranked by after-market performance: January - December 2014

Read More

Underwriter performance on all U.S. IPOs, ranked by gross proceeds: January - December 2014

Read More

Underwriter performance on all U.S. IPOs, ranked by after-market performance: January - December 2014

Read More

Lead underwriter performance on all U.S. IPOs, ranked by gross proceeds: January - December 2014

Read More

Lead underwriter performance on all U.S. IPOs, ranked by after-market performance: January - December 2014

Read More

The week's biggest gainers and losers

Read More

BioWorld stock report for public biotechnology companies

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 2, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 2, 2025.
  • Molecule illustration

    Unnatural Products joins Argenx in a $1.5B macrocyclic deal

    BioWorld
    Unnatural Products Inc. notched another collaboration by signing on with Argenx SE in a multitarget research collaboration. Unnatural Products, which is getting...
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • CMS logo and website

    CMS eyes competitive bidding for CGMs, insulin pumps

    BioWorld MedTech
    The U.S. Centers for Medicare & Medicaid Services posted the draft home health rule for calendar year 2026, which includes a proposal to subject continuous...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe